A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Two Doses of an Influenza A/H7N9 Vaccine Administered With or Without MF59 Adjuvant

Trial Profile

A Phase II, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial to Assess the Safety, Reactogenicity and Immunogenicity of Two Doses of Multimeric-001 (M-001) Followed by Two Doses of an Influenza A/H7N9 Vaccine Administered With or Without MF59 Adjuvant

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Influenza A virus H7N9 vaccines; MF 59
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 10 Aug 2017 Planned initiation date changed from 10 Aug 2017 to 31 Aug 2017.
    • 20 Jul 2017 Planned initiation date changed from 13 Jul 2017 to 10 Aug 2017.
    • 15 Jun 2017 Planned initiation date changed from 29 Jun 2017 to 6 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top